UroGen Q1 net loss $32.3M; JELMYTO revenue up 10% to $18.8M; UGN-102 NDA on track

UroGen Pharma Ltd.

Net loss $32.3M ($0.97/share) vs $30.2M ($1.30) in Q1 2023; JELMYTO revenue $18.8M, +10% YoY.
FY2024 guidance reiterated: JELMYTO revenue $95-102M; operating expenses $175-185M.
UGN-102 rolling NDA submission to complete Q3 2024; ENVISION 12-month DOR data event June 13.
IND accepted for UGN-103; Phase 3 in LG-IR-NMIBC planned for 2024.
Cash $164.5M; OLYMPUS post-hoc shows JELMYTO median duration of response 47.8 months.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

UroGen Pharma Ltd. reported the first quarter ended March 31, 2024 results: revenue $18.8 million, net income net loss of $32.3 million or ($0.97) per basic and diluted share, EPS ($0.97) per basic and diluted share. Guidance reaffirmed.

Period: the first quarter ended March 31, 2024
Revenue: $18.8 million
Net income: net loss of $32.3 million or ($0.97) per basic and diluted share
EPS: ($0.97) per basic and diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

• Post-hoc analysis of OLYMPUS study for JELMYTO shows disease-free periods more than 47.8 months in LG-UTUC • JELMYTO ® demonstrated continued growth with net product sales of $18.8 million in Q1, compared with $17.2 million in Q1 2023 representing ~10% YoY growth • IND accepted for UGN-103, next-generation novel mitomycin-based formulation of UGN-102 to treat

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

UroGen Pharma Ltd. filing history →

Source: SEC EDGAR

accession 0001193125-24-136728

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.